Khiron Life Sciences Corp. (OTCQX: KHRNF) (TSXV:KHRN) (Frankfurt:A2JMZC) released its financial results for the quarter ended September 30, 2022, revealing revenue of CA$3.4 million ($2.5 million), a 4% decrease compared to CA$3.6 million in the Q3 2021.
October 28, 12:35 PM
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list of some of the top executives in the space to keep an eye on.
September 13, 12:13 AM
For the first time ever, the 15th edition of the Benzinga Cannabis Capital Conference, underway in Chicago September 13-14, presented a series of Benzinga Cannabis Awards.
August 29, 9:31 AM
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX: KHRNF) (Frankfurt:A2JMZC) Q2 2022 total revenue was CA$4.5 million ($3.45 million), up 60% year-over-year, driven by growth in the medical cannabis segment in Colombia and the United Kingdom.
These 9 Cannabis Companies Are Leading The Way In Latin America: What Are They Up To And Why Should You Pay Attention?
August 18, 10:15 AM
The Benzinga Cannabis Capital Conference in Chicago, September 13-14, will celebrate the most recognized Latin American cannabis companies.
August 3, 9:05 AM
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX: KHRNF) (Frankfurt:A2JMZC) has completed the acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (OTCQB: LMLLF) (CSE:PHRX).
Benzinga CEO Predicts $1B In Cannabis Deals Closing In Just 2 Days In September: Find Out Where And How!
August 1, 11:21 AM
“We’ve run our numbers and estimate that roughly $1 billion in deals will be closed on September 13 and 14 in Chicago.